Please Wait

Applying Filters...

Nadroparine
KDMF
Table View

Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Nadroparine

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

21 API Suppliers, 10 USDMF, 6 JDMF, 1 KDMF, 8 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

11 Drugs in Development

11 Drugs in Development

FINISHED DOSAGE FORMULATIONS

186 FDF Dossiers, 15 FDA Orange Book, 132 Europe, 21 Canada, 11 South Africa, 7 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - 10,000IU/ML (10,000IU/ML), INJECTABLE;SUBCUTANEOUS - 10,000IU/4ML (2,500IU/ML), INJECTABLE;SUBCUTANEOUS - 12,500IU/0.5ML (25,000IU/ML), INJECTABLE;SUBCUTANEOUS - 15,000IU/0.6ML (25,000IU/ML), INJECTABLE;SUBCUTANEOUS - 18,000IU/0.72ML (25,000IU/ML), INJECTABLE;SUBCUTANEOUS - 2,500IU/0.2ML (12,500IU/ML), INJECTABLE;SUBCUTANEOUS - 5,000IU/0.2ML (25,000IU/ML), INJECTABLE;SUBCUTANEOUS - 7,500IU/0.3ML (25,000IU/ML), INJECTABLE;SUBCUTANEOUS - 95,000IU/3.8ML (25,000IU/ML)

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 1 Kirsch Pharma, 3 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

4 Parenteral, 2 Topical, 1 Solubilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 3 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 16 Regulatory FDF Prices

MARKET PLACE

17 APIs, 43 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 1 Others

$ Xls download

Filters

Log in to download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Laboratorios Farmaceuticos Rovi	Spain	Ilsung IS Co., Ltd.	20250221-211-J-1761	Bemiparin sodium	2025-02-21	ROVI ESCÚZAR, SL	Spain	Avenida de la Serrezuela, 5518130 ESCÚZAR (GRANADA), SPAIN

Contact us
to update this info

Nadroparine

Nadroparine

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

21 API Suppliers

10 USDMF

6 JDMF

1 KDMF

8 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

11 Drugs in Development

FINISHED DOSAGE FORMULATIONS

186 FDF Dossiers

15 FDA Orange Book

132 Europe

21 Canada

11 South Africa

7 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - 10,000IU/ML (10,000IU/ML)

INJECTABLE;SUBCUTANEOUS - 10,000IU/4ML (2,500IU/ML)

INJECTABLE;SUBCUTANEOUS - 12,500IU/0.5ML (25,000IU/ML)

INJECTABLE;SUBCUTANEOUS - 15,000IU/0.6ML (25,000IU/ML)

INJECTABLE;SUBCUTANEOUS - 18,000IU/0.72ML (25,000IU/ML)

INJECTABLE;SUBCUTANEOUS - 2,500IU/0.2ML (12,500IU/ML)

INJECTABLE;SUBCUTANEOUS - 5,000IU/0.2ML (25,000IU/ML)

INJECTABLE;SUBCUTANEOUS - 7,500IU/0.3ML (25,000IU/ML)

INJECTABLE;SUBCUTANEOUS - 95,000IU/3.8ML (25,000IU/ML)

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical

1 Kirsch Pharma

3 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

4 Parenteral

2 Topical

1 Solubilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

3 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

16 Regulatory FDF Prices

MARKET PLACE

17 APIs

43 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM

1 Others

Filters